AdaptHealth Corp. (AHCO)
| Market Cap | 837.81M -29.6% |
| Revenue (ttm) | 3.44B +15.4% |
| Net Income | -406.73M |
| EPS | -2.99 |
| Shares Out | 133.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,686,360 |
| Open | 6.24 |
| Previous Close | 5.91 |
| Day's Range | 5.65 - 6.40 |
| 52-Week Range | 5.21 - 13.43 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 8.86 (+41.04%) |
| Earnings Date | Nov 3, 2026 |
About AHCO
AdaptHealth Corp., together with its subsidiaries, distributes home medical equipment (HME), medical supplies, and home and related services in the United States. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments. The company offers sleep therapy equipment, supplies, and related services, such as continuous positive airway pressure and BiLevel services to individuals suffering from obstructive sleep apnea; oxygen and home mechanical ventilation equipment and supplies and related chronic therapy... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for AHCO stock is "Strong Buy." The 12-month stock price target is $8.86, which is an increase of 41.04% from the latest price.
News
AdaptHealth Earnings Call Transcript: Q3 2026
Q3 revenue and adjusted EBITDA beat guidance as the largest capitated contract improved, while FY26 revenue and EBITDA outlooks rose. Free cash flow guidance was reduced, with debt reduction, cost discipline, and contract-margin recovery central to the outlook.
AdaptHealth Earnings release: Q3 2026
AdaptHealth released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
AdaptHealth Slides: Q3 2026
AdaptHealth has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
AdaptHealth Quarterly report: Q3 2026
AdaptHealth has published its Q3 2026 quarterly earnings report on November 3, 2026.
AdaptHealth reports Q3 EPS ($1.13) vs 17c last year
Reports Q3 revenue $745.6M, consensus $725.87M. “In the third quarter, we delivered strong organic revenue growth and exceeded our guidance for revenue, Adjusted EBITDA and free cash flow,” said Suzan...
AdaptHealth raises FY26 revenue view to $2.88B-$2.9B from $2.85B-$2.89B
Consensus $2.88B
AdaptHealth Corp. Announces Third Quarter 2026 Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medi...
AdaptHealth Corp. Announces Third Quarter 2026 Earnings Release Date and Conference Call
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medi...
AdaptHealth price target lowered to $9 from $10 at Baird
Baird lowered the firm’s price target on AdaptHealth (AHCO) to $9 from $10 and keeps an Outperform rating on the shares. The firm updated its model following the Baird conference.
AdaptHealth Transcript: 2026 Global Healthcare Conference
Leadership transitions and strategic divestitures have positioned the company to minimize competitive bidding risk and focus on core sleep, respiratory, and HME markets. Operational improvements, contract renegotiations, and portfolio management are expected to drive growth and margin expansion over the next several years.
AdaptHealth Transcript: 2026 Jefferies Healthcare Services and Technology Conference
Leadership changes and portfolio streamlining are positioning the business for national scale and growth, with a focus on sleep, respiratory, and home medical equipment. Capitated contracts and technology adoption are driving organic growth, while divestiture proceeds will reduce debt and fund expansion.
AdaptHealth To Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home ...
AdaptHealth names Harriss Currie as new CFO
AdaptHealth (AHCO) announced that its Board of Directors has named Harriss T. Currie as its Chief Financial Officer, effective September 9, 2026. Mr. Currie will assume CFO responsibilities from Jason...
AdaptHealth Appoints Harriss Currie as Chief Financial Officer
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home ...
ReDream Brands Launches as the Leading Direct-to-Consumer Platform for Sleep Apnea and Sleep Health
New platform brings four of the industry's most recognized direct-to-consumer brands together to serve the cash-pay obstructive sleep apnea (OSA) market across North America NEW YORK, Aug. 17, 2026 /P...
AdaptHealth Corp. Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information
CONSHOHOCKEN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from the AdaptHealth Corp. (Nasdaq: AHCO) data...
AdaptHealth Transcript: Canaccord Genuity's 46th Annual Growth Conference
The business completed a major portfolio shift, exiting diabetes and e-commerce to focus on sleep and respiratory, driving strong growth and record referrals. Technology investments and a large West Coast capitated contract are key growth drivers, with capital prioritized for organic expansion and debt reduction.
AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $AHCO--AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law.
AdaptHealth Corp. to Participate in Upcoming Investor Conferences
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medi...
AdaptHealth price target lowered to $10 from $14 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on AdaptHealth (AHCO) to $10 from $14 and keeps a Buy rating on the shares.
AdaptHealth price target lowered to $8 from $15 at RBC Capital
RBC Capital lowered the firm’s price target on AdaptHealth (AHCO) to $8 from $15 and keeps an Outperform rating on the shares.
AdaptHealth price target lowered to $9 from $14 at Truist
Truist lowered the firm’s price target on AdaptHealth (AHCO) to $9 from $14 and keeps a Buy rating on the shares. The Q2 results disappointed due to contract, portfolio, and…
AdaptHealth price target lowered to $10 from $15 at Baird
Baird analyst Eric Coldwell lowered the firm’s price target on AdaptHealth (AHCO) to $10 from $15 and keeps an Outperform rating on the shares.
AdaptHealth price target lowered to $10 from $16 at Canaccord
Canaccord lowered the firm’s price target on AdaptHealth (AHCO) to $10 from $16 and keeps a Buy rating on the shares. The firm updated its model following disappointing Q2 results…
AdaptHealth Earnings Call Transcript: Q2 2026
Organic growth reached 16% with strong gains in Sleep and Respiratory Health, but profitability was pressured by West Coast contract inefficiencies and a sudden supplier price hike. Strategic divestitures and restructuring are expected to improve margins and focus future growth.